Daiichinkyo Co (TSE:4568) Other Current Liabilities : 円119,478 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Other Current Liabilities?

Daiichinkyo Co's other current liabilities for the quarter that ended in Mar. 2024 was 円119,478 Mil.

Daiichinkyo Co's quarterly other current liabilities increased from Sep. 2023 (円33,593 Mil) to Dec. 2023 (円101,509 Mil) and increased from Dec. 2023 (円101,509 Mil) to Mar. 2024 (円119,478 Mil).

Daiichinkyo Co's annual other current liabilities increased from Mar. 2022 (円43,180 Mil) to Mar. 2023 (円43,361 Mil) and increased from Mar. 2023 (円43,361 Mil) to Mar. 2024 (円119,478 Mil).

Daiichinkyo Co Other Current Liabilities Historical Data

The historical data trend for Daiichinkyo Co's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Other Current Liabilities Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Other Current Liabilities

Get a 7-Day Free Trial

Daiichinkyo Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Daiichinkyo Co Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Daiichinkyo Co Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (TSE:4568) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (TSE:4568) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (TSE:4568) Headlines

No Headlines